Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

In a report released yesterday, Evan Seigerman from BMO Capital maintained a Buy rating on Merck & Company (MRK – Research Report), with a price target of $136.00. Evan Seigerman has given his ...

Merck & Company ( (MRK)) has released its Q3 earnings. Here is a breakdown of the information Merck & Company presented to its investors. Merck & Company, also known as MSD outside the United ...

Welcome to the Merck & Company Q3 sales and earnings conference call. [Operator instructions] This call is being recorded.

The Gardasil franchise is the company's second largest sales driver behind Keytruda, and Merck remains steadfast it can garner more than $11 billion from the key product in 2030. Fewer than 10% of ...

InProcess-LSP are a young organization, founded in 2014, they have since emerged as providers of groundbreaking process analytical technology for nanoparticle characterization. This article provides a ...

Oct 23 (Reuters) - Merck (MRK.N), opens new tab has acquired Modifi Biosciences for as much as $1.3 billion, gaining access to its experimental cancer therapies, the privately held biotech firm ...

No matter how well the stock market is performing, investors can always find some companies that aren't keeping pace with broader equities. This year, pharmaceutical giant Merck (NYSE: MRK ...

Are you a print subscriber? Activate your account. By Garett Sloane - 2 hours 35 min ago By Gillian Follett - 2 hours 35 min ago By E.J. Schultz - 2 hours 35 min ago By Jack Neff - 2 hours 35 min ...

Oct 17 (Reuters) - German science and technology group Merck (MRCG.DE), opens new tab is open to more acquisitions for its Life Science business after announcing in May it would buy Mirus Bio for ...

Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

German pharma and technology giant Merck has announced a €5 million (£4.2m) investment in Scotland that will create further jobs at its diagnostics and blood typing facility in Livingston.